Age: 72.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, SARS-CoV-2 antibody test
Clinical narrative: Tested positive this morning 5/25/2022 after testing negative 5/23/2022 and 5/21/2022. Slight sore throat; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested positive this morning 5/25/2022 after testing negative 5/23/2022 and 5/21/2022. Slight sore throat) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Allergic reaction was reported for an unspecified drug.    In February 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 25-May-2022 at 7:00 AM, the patient experienced COVID-19 (Tested positive this morning 5/25/2022 after testing negative 5/23/2022 and 5/21/2022. Slight sore throat). At the time of the report, COVID-19 (Tested positive this morning 5/25/2022 after testing negative 5/23/2022 and 5/21/2022. Slight sore throat) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-May-2022, SARS-CoV-2 antibody test: negative (Negative) Negative. On 23-May-2022, SARS-CoV-2 antibody test: negative (Negative) Negative. On 25-May-2022, SARS-CoV-2 antibody test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. In February 2021 at 1:15pm , the patient received Moderna vaccine. It was reported that the patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. Device Date was reported as 25-May-2022.  Company Comment: This spontaneous case reported by a patient concerns a 72-year-old female patient, with no reported medical history, who experienced unexpected, non-serious Covid19, approximately 1 year and 3 months after receiving a dose of mRNA-1273.  She was given Nirmatrelvir/Ritonavir for around 5 days, after which she tested negative for Covid19 twice.  However, around 1 week after completing Nirmatrelvir/Ritonavir, she developed slight sore throat, then tested positive for Covid19.  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case reported by a patient concerns a 72-year-old female patient, with no reported medical history, who experienced unexpected, non-serious Covid19, approximately 1 year and 3 months after receiving a dose of mRNA-1273.  She was given Nirmatrelvir/Ritonavir for around 5 days, after which she tested negative for Covid19 twice.  However, around 1 week after completing Nirmatrelvir/Ritonavir, she developed slight sore throat, then tested positive for Covid19.  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.